Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Biotechnology

Healthcare
$3.89 +0.79%

+$0.03 today

Market cap
$169.16M
Beta
1.24
P/E (TTM)
1.4
EPS (TTM)
$2.70
Dividend yield
6.54%
52W Low $1.98High $5.01

Volume 0.16M

Average 0.16M

ORMP Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Oramed Pharmaceuticals Inc.NASDAQ: ORMP

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $30K rose 0.0% year over year, ahead of the -27.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +27.8% a year.

Context

  • Depreciation & amortization amounted to 6.0% of revenue in FY2025.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +0.0% holds above the trailing-twelve-month pace of -27.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30K+0.0% QoQ
Last fiscal yearDec 2025
$121K-37.3% YoY
LTMMar 2026
$121K-27.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-37.3%——
3-year CAGR+27.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
121K USD
Year-over-year change
-37.3%
4-year CAGR
+12.0%

Depreciation & Amortization vs competitors

How ORMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -27.5% is the 9th highest of 10, against a peer median of -7.1%.
  • Over three fiscal years its annual growth of +27.8% compares with a peer median of -11.4%.
ORMP Competitors
Depreciation & Amortization for ORMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CLNNClene Inc.LTM Mar 2026$1.45M USD-11.2%+13.6%1079.1%
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.4%1100.0%
IMAImageneBio IncLTM Mar 2026$616K USD+72.1%-24.1%—
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
OVIDOvid Therapeutics Inc.LTM Mar 2026$168K USD-72.2%-41.8%2.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$121K USD-27.5%+27.8%—
COYACoya Therapeutics, Inc.LTM Mar 2026$23.33K USD-14.7%+0.0%0.3%
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$16.88K USD+36.5%+20.6%—
Peer median (excluding ORMP) —-7.1%-11.4%364.3%

Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Aug 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.24M)(36.56M)5.53M(19.06M)64.02M
Depreciation & Amortization77K58K196K193K121K
Deferred Income Tax00007.91M
Stock-Based Compensation00005.99M
Change in Working Capital(1.32M)(943K)(2.7M)3.2M(1.91M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.06M(376K)(2.23M)3.53M1.13M
Other Working Capital(3.38M)(567K)(471K)(325K)(3.04M)
Other Non-Cash Items2.3M8.75M(13.32M)7.26M(85.28M)
Operating Cash Flow(21.18M)(28.7M)(10.3M)(8.41M)(9.15M)
Capital Expenditures(375K)(496K)(254K)(18K)(1.93M)
Acquisitions (Net)1.5M24K00(7.25M)
Purchases of Investments(53.82M)(154.41M)(190.92M)(55.76M)(88.51M)
Sales of Investments30.43M185.09M118.14M161.65M96.88M
Other Investing Activities(1K)2K0(60K)6.25M
Investing Cash Flow(22.26M)30.21M(73.04M)105.82M5.44M
Debt Repayment——49.55M(49.55M)0
Common Stock Issued101.39M11.56M2.43M00
Common Stock Repurchased000(2.48M)(4.74M)
Dividends Paid00000
Other Financing Activities000(2K)0
Financing Cash Flow101.39M11.56M51.98M(52.04M)(4.74M)
Effect of Forex Changes2K(49.85M)(54K)(4K)(30K)
Net Change in Cash57.95M(36.78M)(31.41M)45.37M(8.47M)
Free Cash Flow(21.56M)(29.2M)(10.55M)(8.43M)(11.08M)

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

Intrinsic Alpha fair value

Locked

Current Price

$3.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.